Amazon uses third-party seller data to copy the site’s most popular products, an antitrust report by the House Judiciary Committee alleged on Wednesday.
Former Amazon sellers told an antitrust subcommittee the company released new products almost identical to their own and “killed” their sales.
Amazon has denied accusations of this behavior in the past.
“We have a policy against using seller-specific data to aid our private-label business,” Amazon CEO Jeff Bezos said in July.
Visit Business Insider’s homepage for more stories.
The House Judiciary antitrust subcommittee said it has uncovered evidence that Amazon uses detailed data from third-party sellers to copy popular products and push some sellers out of business — something the tech giant has consistently denied.
The subcommittee said it had heard “repeated” concerns from both former employees and third-party sellers that Amazon uses seller data to either copy products or source the product directly from the manufacturer.
Ask 100 business leaders to identify their companies’ most important assets, and I’ll bet 99 will say the same thing: “Our people.”
Most of the time, they’ll be right. Often enough, they’ll actually believe it.
But that simple, near-universal truth belies a big problem, something you probably face in your business, too — namely, how do you find, recruit, and retain these truly excellent people?
With that in mind, let’s talk about Elon Musk.
Between Tesla, SpaceX, Neuralink, and The Boring Company, recruiting and retention is a constant concern for Musk. So, I paid attention over the weekend, when he asked any engineer who had applied to Neuralink, and who thought their application had been “incorrectly overlooked,” to respond to him on Twitter.
It’s not the first time Musk has used Twitter like this. For example, earlier this year he called on Twitter for applicants who wanted to work
Key proteins used by coronavirus for its reproduction being modeled on NSF-funded Frontera supercomputer by Andres Cisneros research group of the University of North Texas. Research goals include finding ways to improve on COVID-19 therapeutic remdesivir. NSF-funded Frontera allocation awarded to Cisneros through the COVID-19 High Performance Computing Consortium.
In May 2020, the U.S. Food and Drug Administration authorized the antiviral drug remdesivir for emergency treatment of COVID-19, one of only four therapeutics currently with this status. Remdesivir stops the